KEAP1 and lung carcinoma: Galan-Cobo et al. (2019) characterized the metabolic phenotypes of KRAS/LKB1/KEAP1 co-mutant lung cancer. They defined addiction to glutamine metabolism in this subgroup of lung cancer confered high sensitivity to the glutaminase inhibitor CB-839 in vitro and in vivo.